Human T cells that target tumor-specific mutations are attractive for cancer immunotherapy, but obtaining these T cells is challenging. A new study shows that tumor mutation–specific T cells can be isolated from the peripheral blood of patients with melanoma.
References
Rosenberg, S.A. & Restifo, N.P. Science 348, 62–68 (2015).
Schumacher, T.N. & Schreiber, R.D. Science 348, 69–74 (2015).
van Rooij, N. et al. J. Clin. Oncol. 31, e439–e442 (2013).
Rizvi, N.A. et al. Science 348, 124–128 (2015).
Gros, A. et al. Nat. Med. 22, 433–438 (2016).
Gros, A. et al. J. Clin. Invest. 124, 2246–2259 (2014).
Zanetti, M. J. Immunol. 194, 2049–2056 (2015).
Linnemann, C. et al. Nat. Med. 21, 81–85 (2015).
Tran, E. et al. Science 344, 641–645 (2014).
Haber, D.A. & Velculescu, V.E. Cancer Discov. 4, 650–661 (2014).
Lohr, J.G. et al. Nat. Biotechnol. 32, 479–484 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Schumacher, T., Scheper, W. A liquid biopsy for cancer immunotherapy. Nat Med 22, 340–341 (2016). https://doi.org/10.1038/nm.4074
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4074
- Springer Nature America, Inc.
This article is cited by
-
Cancer characterization and diagnosis with SERS-encoded particles
Cancer Nanotechnology (2017)
-
Pathologists and liquid biopsies: to be or not to be?
Virchows Archiv (2016)